US2023100521A1PendingUtilityA1

Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers

69
Assignee: NUTRITION21 LLCPriority: Nov 2, 2018Filed: Oct 4, 2022Published: Mar 30, 2023
Est. expiryNov 2, 2038(~12.3 yrs left)· nominal 20-yr term from priority
Inventors:James R. Komorowski
A61K 31/047A61K 31/045A61K 47/549A61K 47/542A61P 25/00A61K 2300/00A61K 31/198A61P 25/28A61K 47/52A61K 47/55
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to the use of inositol-stabilized arginine silicate complexes (“ASI”) with the addition of free inositol (“I”) to form a composition ASI+I for improving cognitive functioning in humans, particularly video game players.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled) 
     
     
         11 . A composition comprising an active ingredient mixture comprising inositol-stabilized arginine silicate complex (ASI) and free inositol. 
     
     
         12 . The composition of  claim 11 , wherein the composition comprises about 550 mg of the active ingredient mixture. 
     
     
         13 . The composition of  claim 11 , wherein the composition comprises about 1,000 mg of the active ingredient mixture. 
     
     
         14 . The composition of  claim 11 , wherein the composition comprises about 1,500 mg of the active ingredient mixture. 
     
     
         15 . The composition of  claim 11 , wherein the composition comprises about 1,600 mg of the active ingredient mixture. 
     
     
         16 . The composition of  claim 11 , wherein the mass ratio of inositol-stabilized arginine silicate complex to free inositol is about 15:1, about 10:1, or about 1:1. 
     
     
         17 . The composition of  claim 11 , wherein the mass ratio of inositol-stabilized arginine silicate complex to free inositol is about 15:1. 
     
     
         18 . The composition of  claim 11 , wherein the composition is formulated for oral administration. 
     
     
         19 . The composition of  claim 11 , wherein the composition is formulated as a tablet, an aqueous or oil suspension, a dispersible powder or granule, an emulsion, a hard or soft capsule, a syrup, an elixir, or a beverage. 
     
     
         20 . The composition of  claim 11 , wherein the composition is formulated for extended release. 
     
     
         21 . The composition of  claim 11 , wherein the composition further comprises a pharmaceutically acceptable excipient.

Join the waitlist — get patent alerts

Track US2023100521A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.